Mutant p53: one name, many proteins.

There is now strong evidence that mutation not only abrogates p53 tumor-suppressive functions, but in some instances can also endow mutant proteins with novel activities. Such neomorphic p53 proteins are capable of dramatically altering tumor cell behavior, primarily through their interactions with other cellular proteins and regulation of cancer cell transcriptional programs. Different missense mutations in p53 may confer unique activities and thereby offer insight into the mutagenic events that drive tumor progression. Here we review mechanisms by which mutant p53 exerts its cellular effects, with a particular focus on the burgeoning mutant p53 transcriptome, and discuss the biological and clinical consequences of mutant p53 gain of function.

[1]  W. Deppert,et al.  The complex interactions of p53 with target DNA: we learn as we go. , 2003, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[2]  E. Feinstein,et al.  Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway , 2008, Proceedings of the National Academy of Sciences.

[3]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[4]  P. Schirmacher,et al.  Protumorigenic overexpression of stathmin/Op18 by gain‐of‐function mutation in p53 in human hepatocarcinogenesis , 2007, Hepatology.

[5]  J. Fraumeni,et al.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.

[6]  Joost Schymkowitz,et al.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. , 2011, Nature chemical biology.

[7]  S. Sykes,et al.  The p53 family and programmed cell death , 2008, Oncogene.

[8]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[9]  J. Momand,et al.  Heat Shock Protein 84 Forms a Complex with Mutant p53 Protein Predominantly within a Cytoplasmic Compartment of the Cell* , 1996, The Journal of Biological Chemistry.

[10]  Xinbin Chen,et al.  Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis* , 1998, The Journal of Biological Chemistry.

[11]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[12]  David Lane,et al.  p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.

[13]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[14]  C. Stratakis,et al.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. Rotter,et al.  Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis , 2001, The EMBO journal.

[16]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[17]  E. Sugikawa,et al.  Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. , 1999, Anticancer research.

[18]  E. Franco,et al.  Persistent human papillomavirus infection and cervical neoplasia. , 2002, The Lancet. Oncology.

[19]  J. Bourdon,et al.  p53 family members in cancer diagnosis and treatment. , 2010, Seminars in cancer biology.

[20]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[21]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[22]  M. Hsiao,et al.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. , 1994, The American journal of pathology.

[23]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[24]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[25]  P. Gruss,et al.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells , 1984, Nature.

[26]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[27]  Jiandong Chen,et al.  Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization* , 2001, The Journal of Biological Chemistry.

[28]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[29]  S. Berger,et al.  Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity , 1997, Oncogene.

[30]  E. Silbergeld,et al.  P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. , 1996, Environmental health perspectives.

[31]  A. El‐Naggar,et al.  Multiple stress signals activate mutant p53 in vivo. , 2011, Cancer research.

[32]  B. Strauss,et al.  The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. , 1995, Biochemical and biophysical research communications.

[33]  E. Appella,et al.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[34]  N. Basset-Seguin,et al.  TP53 tumor suppressor gene and skin carcinogenesis. , 1994, The Journal of investigative dermatology.

[35]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[36]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[37]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[38]  G. Wahl,et al.  Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures , 2010, Proceedings of the National Academy of Sciences.

[39]  S. Deb,et al.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 , 1996, Molecular and cellular biology.

[40]  M. Tada,et al.  Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. , 2010, Biomedical research.

[41]  V. Rotter,et al.  Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies , 2011, Cancer Gene Therapy.

[42]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[43]  W. Hahn,et al.  Chemosensitivity linked to p73 function. , 2003, Cancer cell.

[44]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Blandino,et al.  Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression , 2006, Oncogene.

[46]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[47]  Erwin G. Van Meir,et al.  Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1 , 2003, Oncogene.

[48]  Y. Sung,et al.  Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding Protein (*) , 1995, The Journal of Biological Chemistry.

[49]  A. Torgeman,et al.  Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. , 2001, Virology.

[50]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Daxi Sun,et al.  Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1* , 2001, The Journal of Biological Chemistry.

[52]  G. Wahl,et al.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.

[53]  K. Aldape,et al.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  I. Simon,et al.  Modulation of the vitamin D3 response by cancer-associated mutant p53. , 2010, Cancer cell.

[55]  Y. Zhang,et al.  Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. , 2011, Current cancer drug targets.

[56]  D. Medina,et al.  Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis , 1998, Oncogene.

[57]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[58]  A. Yang,et al.  Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. , 2005, Cancer cell.

[59]  A. Børresen-Dale,et al.  A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients , 2008, Acta oncologica.

[60]  C. Prives,et al.  Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.

[61]  V. Rotter,et al.  Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy , 2008, Cell cycle.

[62]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Antonio Rosato,et al.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. , 2011, Cancer cell.

[64]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[65]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[66]  G. Blandino,et al.  Mutant p53: an oncogenic transcription factor , 2007, Oncogene.

[67]  R. Poon,et al.  How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer? , 2004, Molecular and Cellular Biology.

[68]  A. Fersht,et al.  Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53 , 2007, Proceedings of the National Academy of Sciences.

[69]  R. Altman,et al.  Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13)* , 2000, The Journal of Biological Chemistry.

[70]  V. Rotter,et al.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.

[71]  U. Moll,et al.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis , 2011, Cell Death and Differentiation.

[72]  W. McGuire,et al.  Prognostic significance of p53 gene alterations in node-negative breast cancer , 2004, Breast Cancer Research and Treatment.

[73]  J. Marine,et al.  Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.

[74]  W. Deppert,et al.  Transcriptional activities of mutant p53: When mutations are more than a loss , 2004, Journal of cellular biochemistry.

[75]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[76]  M. Oren,et al.  Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.

[77]  A. El‐Naggar,et al.  Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. , 2011, The Journal of clinical investigation.

[78]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[79]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[80]  R. Weinberg.  Tumor suppressor genes , 1993, Neuron.

[81]  T. Davison,et al.  p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.

[82]  T. Soussi,et al.  Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73* , 2003, The Journal of Biological Chemistry.

[83]  V. Rotter,et al.  Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences , 1984, Molecular and cellular biology.

[84]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[85]  V. Rotter,et al.  Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function , 2004, Cancer Research.

[86]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[87]  Sook Y. Lee,et al.  Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma , 2000, Oncogene.

[88]  A. Levine,et al.  The Spectrum of Mutations at the p53 Locus , 1995, Annals of the New York Academy of Sciences.

[89]  Wafik S El-Deiry,et al.  Current strategies to target p53 in cancer. , 2010, Biochemical pharmacology.

[90]  V. Rotter,et al.  p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.

[91]  L. Wiesmüller,et al.  Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  W. Deppert,et al.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences , 2009, Nucleic acids research.

[93]  B. Vogelstein,et al.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[94]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[95]  A. Levine.  The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. , 2009, Virology.

[96]  G. Blandino,et al.  Promyelocytic leukemia protein is required for gain of function by mutant p53. , 2009, Cancer research.

[97]  A. Albor,et al.  Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. , 2002, Cancer research.

[98]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[99]  W. Deppert,et al.  Specific binding of MAR/SAR DNA-elements by mutant p53. , 1996, Oncogene.

[100]  K. Wiman,et al.  Pharmacological reactivation of mutant p53: from protein structure to the cancer patient , 2010, Oncogene.

[101]  A. Fersht,et al.  A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  G. Bossi,et al.  Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function* , 2010, The Journal of Biological Chemistry.

[103]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[104]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[105]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[106]  W. Deppert,et al.  Wild-type p53 in cancer cells: when a guardian turns into a blackguard. , 2009, Biochemical pharmacology.

[107]  W. Kaelin,et al.  Role of the newer p53 family proteins in malignancy , 2001, Apoptosis.

[108]  J. Manfredi.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[109]  Ting Wang,et al.  A global suppressor motif for p53 cancer mutants. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[110]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[111]  R. Bristow,et al.  Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53 , 2003, Oncogene.

[112]  B. Groner,et al.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain , 1997, Nature Medicine.

[113]  U. Preuss,et al.  Tumor‐derived p53 mutant C174Y is a gain‐of‐function mutant which activates the fos promoter and enhances colony formation , 2000, International journal of cancer.

[114]  A. Inga,et al.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[115]  E. Domany,et al.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis , 2009, Nature Structural &Molecular Biology.

[116]  W. Deppert,et al.  Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo , 2000, Oncogene.

[117]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[118]  Wensheng Yan,et al.  Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function* , 2009, Journal of Biological Chemistry.

[119]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[120]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[121]  P. Graves,et al.  p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. , 2012, Archives of biochemistry and biophysics.

[122]  C. Prives,et al.  A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.

[123]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[124]  S. Thorgeirsson,et al.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression , 2011, Proceedings of the National Academy of Sciences.

[125]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[126]  R. Mantovani,et al.  Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.

[127]  V. Rotter,et al.  Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. , 2009, Journal of molecular biology.

[128]  Tomas Lindahl,et al.  Repair and genetic consequences of endogenous DNA base damage in mammalian cells. , 2004, Annual review of genetics.

[129]  E. Conseiller,et al.  Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains , 1999, Oncogene.

[130]  L. Attardi,et al.  In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. , 2010, Carcinogenesis.

[131]  M. Eisenstein,et al.  The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs , 2008, Cell cycle.

[132]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[133]  K. Jeang,et al.  Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. , 2002, Cancer research.

[134]  V. Rotter,et al.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.

[135]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[136]  C. Prives,et al.  Mutant p53 gain of function: the NF-Y connection. , 2006, Cancer Cell.

[137]  K. Khanna,et al.  Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11 , 2012, Oncogene.

[138]  Shiyun Ling,et al.  TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73 , 2011, Molecular and Cellular Biology.

[139]  C. Prives,et al.  Unleashing the power of p53: lessons from mice and men. , 2006, Genes & development.

[140]  L. Castagnoli,et al.  Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity* , 2001, The Journal of Biological Chemistry.

[141]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[142]  M. Hollstein,et al.  Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool , 2001, Oncogene.

[143]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[144]  Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. , 2011, Archives of biochemistry and biophysics.

[145]  C. Prives,et al.  The C-terminus of p53: the more you learn the less you know , 2001, Nature Structural Biology.

[146]  V. Rotter,et al.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene , 1984, Cell.

[147]  M. Oren,et al.  Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* , 2002, The Journal of Biological Chemistry.

[148]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[149]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[150]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[151]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[152]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[153]  M. Subler,et al.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.

[154]  A. Chicas,et al.  Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. , 2000, Biochemical and biophysical research communications.

[155]  W. Deppert,et al.  Mutant p53 proteins bind DNA in a DNA structure-selective mode , 2005, Nucleic acids research.

[156]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[157]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[158]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[159]  V. Rotter.  p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[160]  E. White,et al.  Does control of mutant p53 by Mdm2 complicate cancer therapy? , 2008, Genes & development.

[161]  A. Chicas,et al.  p53 represses Sp1 DNA binding and HIV-LTR directed transcription. , 1997, Cellular and molecular biology.

[162]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[163]  G. Evan,et al.  Temporal dissection of p53 function in vitro and in vivo , 2005, Nature Genetics.

[164]  T. Jacks,et al.  The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.

[165]  M. Scian,et al.  Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression , 2005, Molecular and Cellular Biology.

[166]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[167]  G. Evan,et al.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.

[168]  V. Rotter,et al.  ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. , 2011, Omics : a journal of integrative biology.

[169]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[170]  E. Kim,et al.  Interactions of mutant p53 with DNA: guilt by association , 2007, Oncogene.

[171]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[172]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[173]  Wensheng Yan,et al.  Characterization of Functional Domains Necessary for Mutant p53 Gain of Function*♦ , 2010, The Journal of Biological Chemistry.

[174]  V. Rotter,et al.  Transcription regulation by mutant p53 , 2007, Oncogene.

[175]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[176]  Gang Li,et al.  Cancer chemoresistance: The relationship between p53 and multidrug transporters , 2002, International journal of cancer.

[177]  D. Ginsberg,et al.  p53 and E2f: partners in life and death , 2009, Nature Reviews Cancer.

[178]  J. Bartek,et al.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. , 1990, Oncogene.

[179]  C. Bonaïti‐pellié,et al.  Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.

[180]  M Bycroft,et al.  Hot-spot mutants of p53 core domain evince characteristic local structural changes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[181]  A. Bernstein,et al.  Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. , 1988, Oncogene.

[182]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[183]  S. Soddu,et al.  Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas , 2009, The Journal of pathology.

[184]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[185]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[186]  Anindita Das,et al.  Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes , 2004, Oncogene.

[187]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[188]  A. Levine,et al.  Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. , 1995, Oncogene.

[189]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[190]  C. Prives,et al.  Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay , 1998, Oncogene.

[191]  A. Multani,et al.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.

[192]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[193]  L. Vassilev,et al.  Small-molecule inhibitors of the p53-MDM2 interaction. , 2011, Current topics in microbiology and immunology.

[194]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[195]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[196]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[197]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[198]  C. Coffill,et al.  The role of mutant p53 in human cancer , 2011, The Journal of pathology.

[199]  A. Levine,et al.  Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil , 2002, Oncogene.

[200]  D. Bell,et al.  Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53 , 2008, PLoS genetics.

[201]  D. Lane,et al.  Reactivation of p53: from peptides to small molecules. , 2011, Trends in pharmacological sciences.

[202]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[203]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.